Post
EC approves Astellas’ XTANDI for high-risk prostate cancer treatment
The European Commission (EC) has granted approval for label extension to Astellas’ Xtandi to be used as monotherapy or in …
Incyte signs deal to acquire Escient Pharmaceuticals
Incyte has agreed to acquire US-based Escient Pharmaceuticals and its assets, including two first-in-class small molecule antagonists targeting Mas-related G …
Pfizer and BioNTech commence legal action against Moderna in UK court
Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over technology instrumental in …
Novartis reports 25% increase in net income in Q1 2024
Novartis has reported net income from continuing operations of $2.68bn for the first quarter (Q1) of 2024, marking a 25% …
Social prescribing: friend or foe for pharma?
As the number of patients being diagnosed with mental health conditions, diabetes, and other chronic conditions increases, more primary care …
Hepion shelves Phase II NASH trial amid shallow cash resources
Hepion Pharmaceuticals has called it quits on a Phase IIb trial investigating the biotech’s lead drug candidate for the treatment …
Investors advocate for early biotech partnerships for later deal success
Following 2023’s stiff economic environment, companies must prioritise partnerships more than ever in their growth strategies, said Richard Girling, a …
Smaller regulators grasp innovation through international collaboration
Smaller regulatory agencies could introduce more therapies into their national markets through faster regulatory processes, said Dr. Ulf Grawunder, managing …
Targeting mouth cancer with light-activated drugs
With two in five patients with oral cancer dying within five years and 95% of patients requiring life-altering surgery, finding …
EC approves BeiGene’s tislelizumab for three NSCLC indications
BeiGene has announced that its anti-programmed cell death protein 1 (PD-1) monoclonal antibody, tislelizumab, has gained European Commission (EC) approval …
Moderna gets grant for vaccine composition for varicella zoster virus
Moderna has been granted a patent for a nucleic acid vaccine that includes RNA polynucleotides encoding varicella zoster virus antigens. …
Bristol-Myers Squibb gets grant for humanized antibodies binding CD40 for treatment of CD40-related diseases
Bristol-Myers Squibb has patented a pharmaceutical composition containing antibodies that bind to human CD40 without activating it. The antibodies may …
Bayer gets grant for herbicide composition with glyphosate, amidoalkylamine surfactant, and co-surfactant
Bayer has been granted a patent for an herbicidal composition containing glyphosate, amidoalkylamine surfactants, and co-surfactants. The concentrate solution includes …
AstraZeneca gets grant for inhibitors of complement factor d for treating disorders
AstraZeneca has been granted a patent for compounds targeting complement Factor D to regulate the complement cascade and reduce excessive …
Insmed gets grant for treatment of gram-positive pulmonary bacterial infections
Insmed has been granted a patent for lipo-glycopeptide cleavable derivatives to treat bacterial infections, particularly in the lungs. The compounds …